GLPG Stock Recent News

U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.

Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .

GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Mechelen, Belgium; 8 November 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology ( ACR ) Co n vergence 2022 meeting taking place in Philadelphia, Pennsylvania from 10-14 November 2022 .

Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired.

Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Mechelen, Belgium; 24 August 2022, 22 . 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences :

Galapagos NV (NASDAQ:GLPG ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Officer Michele Manto - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Jason Gerberry - Bank of America Charlie Mabbutt - Bernstein James Gordon - JPMorgan Matthew Harrison - Morgan Stanley Phil Nadeau - Cowen & Co Jeroen Van den Bossche - KBC Securities Dane Leone - Raymond James Rosie Turner - Jefferies Operator Good day and thank you for standing by. Welcome to the First Half 2022 Financial Results Conference Call.